Press Releases Year: - Any -2024202320222021202020192018201720162015201420132012201120102009 Items per page 102550 December 1, 2010 Summary ToggleMerrimack Pharmaceuticals Initiates Enrollment in Phase 1 Combination Study of MM-121 and paclitaxel in Gynecologic and Breast Cancers November 8, 2010 Summary ToggleMerrimack Pharmaceuticals Awarded $2.44 Million in Grants Under the Patient Protection and Affordable Care Program Merrimack one of the top 10 grant recipients out of approximately 3,000 companies across the United States July 22, 2010 Summary ToggleMerrimack Pharmaceuticals and sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 and exemestane in Breast Cancer The trial, enrolling patients at multiple centers across the United States, is part of a broad Phase 2 program for MM-121 launched by Merrimack and sanofi-aventis this year June 17, 2010 Summary ToggleMelissa Kemp, Ph.D. Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc. June 3, 2010 Summary ToggleMerrimack Pharmaceuticals’ MM-111 Phase 1/2 Trial Design to be Presented at the 2010 ASCO Annual Meeting MM-111 is one of the lead candidates in Merrimack’s pipeline of novel, cancer antibodies May 26, 2010 Summary ToggleCo-Founder Gavin MacBeath, Ph.D. joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research May 17, 2010 Summary ToggleMerrimack Pharmaceuticals Initiates Enrollment in a Phase 1 /2 Combination Study of MM?111 and Herceptin® in Patients with Advanced Her2 Positive Breast Cancer April 30, 2010 Summary ToggleMerrimack to Present at BIO on the Development of MM-111, a Novel Bispecific ErbB2/ErbB3 Antibody with Potent Anti-Tumor Activity Modeling and Simulation used to Develop Optimal Bispecific Antibody for Inhibition of ErbB3 Signaling in ErbB2 Over-Expressing Tumors April 17, 2010 Summary ToggleMerrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of the American Association for Cancer Research (AACR) MM-121 studies in breast cancer models and xenograft response prediction April 5, 2010 Summary ToggleMerrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance Pagination First page First Previous page Previous … Page 26 Page 27 Current page 28 Page 29 Next page Next Last page Last